Bonk (NASDAQ:BNKK) Director Acquires $11,700.00 in Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy acquired 7,500 shares of Bonk stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $1.56 per share, with a total value of $11,700.00. Following the completion of the transaction, the director owned 73,341 shares of the company’s stock, valued at approximately $114,411.96. This trade represents a 11.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mitchell Austin Rudy also recently made the following trade(s):

• On Tuesday, June 16th, Mitchell Austin Rudy acquired 2,500 shares of Bonk stock. The stock was bought at an average cost of $1.32 per share, for a total transaction of $3,300.00.
• On Wednesday, June 10th, Mitchell Austin Rudy purchased 12,000 shares of Bonk stock. The stock was bought at an average price of $1.37 per share, for a total transaction of $16,440.00.
• On Thursday, April 9th, Mitchell Austin Rudy purchased 31,055 shares of Bonk stock. The stock was bought at an average cost of $2.82 per share, for a total transaction of $87,575.10.

Bonk Stock Down 7.1%

Bonk stock opened at $1.45 on Friday. The company’s 50-day moving average price is $2.07 and its two-hundred day moving average price is $2.95. The stock has a market cap of $11.60 million, a P/E ratio of -0.31 and a beta of 1.85. Bonk, Inc. has a twelve month low of $1.25 and a twelve month high of $46.90.

Bonk (NASDAQ:BNKK) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.79 million for the quarter. Bonk had a negative return on equity of 148.62% and a negative net margin of 838.37%.

Analysts Set New Price Targets

BNKK has been the subject of a number of recent research reports. Wall Street Zen cut shares of Bonk from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. Weiss Ratings lowered shares of Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bonk

Several large investors have recently modified their holdings of BNKK. Geode Capital Management LLC bought a new stake in shares of Bonk in the fourth quarter worth $128,000. Jane Street Group LLC acquired a new stake in shares of Bonk in the fourth quarter valued at about $96,000. Steward Partners Investment Advisory LLC bought a new position in shares of Bonk during the fourth quarter worth about $37,000. Finally, State Street Corp bought a new position in shares of Bonk during the fourth quarter worth about $33,000. Institutional investors own 12.55% of the company’s stock.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.